Johnson & Johnson

Johnson & Johnson has been ordered to pay $55 million to a woman who claims its talcum powder caused her ovarian cancer, the second such judgment against the manufacturer in three months.

Johnson & Johnson has ramped up its ambitious project to learn how to predict who will develop particular diseases and find therapies to prevent or stop the disease early, when it's most treatable.

Johnson & Johnson posted a 28 percent jump in fourth-quarter profit, beating Wall Street expectations, as the sale of part of its now-restructuring medical devices business offset the strong dollar and multiple charges. The results pushed up shares of the Dow component more than 3 percent.

Johnson & Johnson expects to cut about 3,000 jobs over the next two years as the health care conglomerate works to restructure its medical devices business.

A New Jersey drug company is testing a new HIV medication that may keep the virus at bay, but medical professionals say that doesn't mean the threat of the disease has been eradicated.

NEW YORK (AP) -- Boston Scientific says it will pay $600 million to settle with drugmaker Johnson & Johnson over the medical device maker's $27 billion acquisition of Guidant Corp. in 2006.

Arkansas Attorney General Dustin McDaniel said Thursday he plans to ask the state Supreme Court to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson over the marketing of the antipsychotic drug Risperdal.

Johnson & Johnson has accepted an offer of about $4 billion from the private equity firm The Carlyle Group to buy its Ortho-Clinical Diagnostics business.

New Jersey will get roughly $18 million from a national settlement resolving allegations that Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., engaged in unlawful marketing practices to promote sales of their antipsychotic drugs Risperdal and Invega.

An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government advisers who say the medication should be approved to treat patients infected with the liver-destroying virus.